CureVac Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Alexander Zehnder
Chief Executive Officer (CEO)
€978.3k
Compensación total
| Porcentaje del salario del CEO | 51.1% |
| Permanencia del CEO | 1.1yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 1.3yrs |
| Promedio de permanencia en la Junta Directiva | 8.2yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20
CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
Mar 03CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma
Feb 04Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)
Jan 27CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates
Jan 11CureVac, Bayer agree to COVID-19 vaccine alliance - report
Jan 07Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?
Dec 23Curevac advances COVID-19 vaccine candidate to Phase 3 trial
Dec 21Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | €978k | €500k | -€260m |
Compensación vs. Mercado: La compensación total de Alexander($USD1.05M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Alexander con los resultados de la empresa.
CEO
Alexander Zehnder (53 yo)
1.1yrs
Permanencia
€978,331
Compensación
Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Member of Management Board | 1.1yrs | €978.33k | sin datos | |
| MD, CFO & Member of Management Board | 7.6yrs | €654.18k | 0.032% € 213.0k | |
| COO, Member of Management Board & MD | 2.8yrs | €600.74k | 0.00093% € 6.1k | |
| Chief Development Officer | 1.3yrs | €614.49k | sin datos | |
| Senior VP & Area Head of Oncology | 1.3yrs | €284.15k | sin datos | |
| Vice President Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| General Counsel | no data | sin datos | sin datos | |
| Head of Corporate Communications | no data | sin datos | sin datos | |
| Head of Human Resources | no data | sin datos | sin datos | |
| Senior Vice President of Technology | no data | sin datos | sin datos | |
| Senior Vice President of Science & Innovation | no data | sin datos | sin datos | |
| Head of Intellectual Property | no data | sin datos | sin datos |
1.3yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CVAC no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Scientific Director of Immunology and Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Supervisory Board Member | 4.9yrs | €96.25k | 0.0011% € 7.2k | |
| Member of Scientific Advisory Board | 8.2yrs | sin datos | sin datos | |
| Independent Director of Supervisory Board | less than a year | €51.03k | sin datos | |
| Independent Chairman of Supervisory Board | 8.8yrs | €123.75k | 0.0031% € 20.1k | |
| Member of Scientific Advisory Board | 8.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.2yrs | sin datos | sin datos | |
| Supervisory Board Member | 8.8yrs | €96.25k | 0.0014% € 9.2k | |
| Member of Scientific Advisory Board | 8.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.2yrs | sin datos | sin datos |
8.2yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de CVAC se considera experimentada (8.1 años de antigüedad promedio).